Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Bayer Pharma Aktiengesellschaft patents


Recent patent applications related to Bayer Pharma Aktiengesellschaft. Bayer Pharma Aktiengesellschaft is listed as an Agent/Assignee. Note: Bayer Pharma Aktiengesellschaft may have other listings under different names/spellings. We're not affiliated with Bayer Pharma Aktiengesellschaft, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "B" | Bayer Pharma Aktiengesellschaft-related inventors


Novel aryl-cyanoguanidine compounds

The present invention relates to protein-lysine n-methyltransferase smyd2 (set and mynd domain-containing protein 2) inhibitors, in particular smyd2-inhibitory substituted cyanoguanidine-pyrazolines of general formula (i), wherein r1, r3, r4, r5 and n have the meaning as described and defined herein, as well as to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyperproliferative disorders, in particular for cancer, respectively tumour disorders. The present invention furthermore relates to the use of smyd2 inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility.. ... Bayer Pharma Aktiengesellschaft

Novel aryl-cyanoguanidine compounds

The present invention relates to protein-lysine n-methyltransferase smyd2 (set and mynd domain-containing protein 2) inhibitors, in particular smyd2-inhibitory substituted cyanoguanidine- pyrazolines of general formula (i), wherein r1, r2, r3, r4 and r5 have the meaning as described and defined herein, as well as to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyperproliferative disorders, in particular for cancer, respectively tumour disorders. The present invention furthermore relates to the use of smyd2 inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility.. ... Bayer Pharma Aktiengesellschaft

Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.. . ... Bayer Pharma Aktiengesellschaft

Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating multiple myeloma

The present invention relates to the use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine (compound a), more particularly (+)-4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine (compound a′), for treating multiple myeloma.. . ... Bayer Pharma Aktiengesellschaft

Heterocyclylmethyl-thienouracile as antagonists of the adenosine-a2b-receptor

The present application relates to novel thieno[2,3-d]pyrimidine-2,4-dione (“thienouracil”) derivatives bearing a particular type of (azaheterocyclyl)methyl substituent, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of pulmonary and cardiovascular disorders and of cancer.. . ... Bayer Pharma Aktiengesellschaft

Nucleic acids and host cells expressing antibodies capable of binding to the coagulation factor xia and uses thereof

The present invention relates to antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.. . ... Bayer Pharma Aktiengesellschaft

1,3,4-thiadiazol-2-yl-benzamide derivatives as inhibitors of the wnt signalling pathway

The present invention relates to inhibitors of the wnt signalling pathways of general formula (i) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

N-phenyl-(morpholin-4-yl or piperazinyl)acetamide derivatives and their use as inhibitors of the wnt signalling pathways

The present invention relates to inhibitors of the wnt signalling pathways of general formula (i) wherein la represents *ch2** or *Δ**; wherein indicates the point of attachment to the carbonyl group, and ** indicates the point of attachment to r1; lb represents *n(h)—c(═o)** or *c(═o)—n(h)**; wherein * indicates the point of attachment to r2, and ** indicates the point of attachment to the phenyl group; r1 represents a group selected from: (aa); wherein * indicates the point of attachment to la, r2 represents: (bb) wherein * indicates the point of attachment to r3, and ** indicates the point of attachment to lb r3 represents a group selected from: (cc); wherein * indicates the point of attachment to r2; r4 and r5 represent a hydrogen atom; and r6 represents a halogen atom or group selected from: —ch3, —o—ch3, —o—chf2, —o—cf3, and —o-cyclopropyl; to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular, of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

Substituted pyrazolo[1,5-a]-pyridine-3-carboxamides and use thereof

The present application relates to novel substituted pyrazolo[1,5-a]pyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.. . ... Bayer Pharma Aktiengesellschaft

Substituted n-bicyclo-2-aryl-quinolin-4-carboxamides and use thereof

The present application relates to novel substituted n-bicyclo-2-arylquinoline-4-carboxamide derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of fibrotic and inflammatory disorders.. . ... Bayer Pharma Aktiengesellschaft

3-carbamoylphenyl-4-carboxamide and isophtalamide derivatives as inhibitors of the wnt signalling pathway

The present invention relates to inhibitors of the wnt signalling pathways of general formula (i) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients, in which: r1 represents a group selected from: c1-c3-alkoxy-c2-c3-alkyl-, (a), (b), (c), (d), (e), (f), (g) or (h); wherein * indicates the point of attachment to the rest of the molecule; r2 represents a group selected from: (i), (j) or (k); wherein * indicates the point of attachment to the rest of the molecule.. . ... Bayer Pharma Aktiengesellschaft

Stabilization adrenomedullin derivatives and use thereof

The invention relates to novel, biologically active, stabilized adrenomedullin (adm) compounds. The invention further relates to the compounds for use in a method for the treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders, and to medicaments comprising the compounds for treatment and/or prevention of cardiovascular, edematous and/or inflammatory disorders.. ... Bayer Pharma Aktiengesellschaft

N-substituted 8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyrazin-3-carboxamide derivatives as stimulators of soluble guanylate cyclase (sgc) for the treatment of cardiovascular diseases

The present application relates to novel substituted imidazo[1,2-a]pyrazine carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.. . ... Bayer Pharma Aktiengesellschaft

6-hydroxybenzofuranyl- and 6-alkoxybenzofuranyl-substituted imidazopyridazines

The present invention relates to 6-hydroxybenzofuranyl- and 6-alkoxybenzofuranyl-substituted imidazopyridazine compounds of general formula (i) in which r1 and r2 are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

01/18/18 / #20180016272

4h-pyrrolo[3,2-c]pyridin-4-one derivatives

Compound of formula (i), processes for their production and their use as pharmaceuticals.. . ... Bayer Pharma Aktiengesellschaft

01/18/18 / #20180015176

Antibody-drug conjugates (adcs) of ksp inhibitors with aglycosylated anti-tweakr antibodies

The present application relates to novel binder drug conjugates (adcs), to active metabolites of these adcs, to processes for preparing these adcs, to the use of these adcs for the treatment and/or prophylaxis of diseases and to the use of these adcs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.. ... Bayer Pharma Aktiengesellschaft

01/04/18 / #20180000690

Apparatus for transferring a liquid between a storage container and at least one further use container

An apparatus for transferring a liquid between a storage container and at least one further use container has a storage-container sealing portion for leaktight abutment of a main body of the transfer apparatus against the storage container. A hollow-needle assembly has a hollow needle. ... Bayer Pharma Aktiengesellschaft

12/28/17 / #20170368069

Use of 4-(4-fluoro-2-methoxyphenyl)-n--1,3,5-triazin-2-amine for treating leukemias

The present invention relates to the use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine (compound a), more particularly (+)-4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine (compound a′), for treating leukemias, in particular acute leukemias, preferably acute myeloid leukemias.. . ... Bayer Pharma Aktiengesellschaft

12/14/17 / #20170354620

Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof

The present invention relates to substituted pyridyl-cycloalkyl-carboxylic acids of general formula (i), to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular in mammals, such as diseases associated with pains, or for the treatment or prophylaxis of pain syndromes (acute and chronic), inflammatory-induced pain, pelvic pain, cancer-associated pain, endometriosis-associated pain as well as endometriosis and adenomyosis as such, cancer as such, and proliferative diseases as such like endometriosis.. . ... Bayer Pharma Aktiengesellschaft

12/07/17 / #20170349570

New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs

The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, copd, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.. . ... Bayer Pharma Aktiengesellschaft

11/30/17 / #the present invention covers [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1h-1,2,3-triazol-4-yl)methanone compounds of general formula (i):

Bayer Pharma Aktiengesellschaft

. . ... Bayer Pharma Aktiengesellschaft

11/30/17 / #20170342064

Compounds for the treatment of cancer

The present invention relates to prodrug derivatives of mps-1 kinase inhibitors, and their use for the treatment and/or prophylaxis of diseases.. . ... Bayer Pharma Aktiengesellschaft

11/30/17 / #20170342034

Novel aryl-cyanoguanidine compounds

The present invention relates to protein-lysine n-methyltransferase smyd2 (set and mynd domain-containing protein 2) inhibitors, in particular smyd2-inhibitory substituted cyanoguanidine-pyrazolines of general formula (i) wherein r1, r2, r3, r4, r5, x and r have the meaning as described and defined herein, as well as to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyper-proliferative disorders, in particular for cancer, respectively tumour disorders. The present invention furthermore relates to the use of smyd2 inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility.. ... Bayer Pharma Aktiengesellschaft

11/23/17 / #20170334917

Piperidinylpyrazolopyrimidinones and their use

The present application relates to novel substituted piperidinylpyrazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired hemostatic disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of heavy menstrual bleeding, postpartum hemorrhage, hemorrhagic shock, hemorrhagic cystitis, gastrointestinal hemorrhage, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.. . ... Bayer Pharma Aktiengesellschaft

11/23/17 / #20170334899

Amino-substituted isothiazoles

The present invention relates to amino-substituted isothiazoles of general formula (i): in which a, r1 and r2 are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

11/16/17 / #20170327505

Synthesis of copanlisib and its dihydrochloride salt

The present invention relates to a novel method of preparing copanlisib, and copanlisib dihydrochloride, to novel intermediate compounds, and to the use of said novel intermediate compounds for the preparation of said copanlisib.. . ... Bayer Pharma Aktiengesellschaft

11/09/17 / #20170320861

Benzimidazol-2-amines as midh1 inhibitors

The present invention relates to benzim-idazol-2-amines of general formula (i) in which r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11 and r12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

11/09/17 / #20170320854

Amide-substituted pyridinyltriazole derivatives and uses thereof

The present invention relates to novel 5-(carboxamide)-1-pyridinyl-1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.. . ... Bayer Pharma Aktiengesellschaft

11/09/17 / #20170319549

1-cyclohexyl-2-phenylaminobenzimidazoles as midh1 inhibitors for the treatment of tumors

The present invention relates to benzimidazol-2-amines of general formula (i) in which r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11 and r12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

10/26/17 / #20170305912

Process for the preparation of 3-phenyl/heteroaryl-6-phenoxy-8-alkylamino-imidazo[1,2-b]pyridazine derivatives

A process for the preparation of 3-phenyl/heteroaryl-6-phenoxy-8-alkylamino-imidazo[1,2-b]pyridazine derivatives and intermediates of this process. A crystalline form of n-cyclopropyl-4-{6-(2,3-difluor-4-methoxyphenoxy)-8-[(3,3,3-trifluorpropyl)amino]imidazo[1,2-b]pyridazin-3-yl}-2-methylbenzamide. ... Bayer Pharma Aktiengesellschaft

10/26/17 / #20170305882

Benzyl substituted indazoles as bub1 kinase inhibitors

Compounds of formula (i) and their use as pharmaceuticals.. . ... Bayer Pharma Aktiengesellschaft

10/26/17 / #20170304278

Heteroaryl-substituted imidazo[1,2-a]pyridines and their use

The present application relates to novel heteroaryl-substituted imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.. . ... Bayer Pharma Aktiengesellschaft

10/12/17 / #20170291892

Substituted oxopyridine derivatives

The invention relates to substituted oxopyridine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.. . ... Bayer Pharma Aktiengesellschaft

10/05/17 / #20170283412

Substituted oxopyridine derivatives

The invention relates to substituted oxopyridine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.. . ... Bayer Pharma Aktiengesellschaft

10/05/17 / #20170283396

Diaminoheteroaryl substituted indazoles

Compounds of formula (i) which are inhibitors of bub 1 kinase, processes for their production and their use as pharmaceuticals.. . ... Bayer Pharma Aktiengesellschaft

09/28/17 / #20170275282

Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives

The invention relates to substituted pyridobenzazepine and pyridobenzazocine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.. . ... Bayer Pharma Aktiengesellschaft

09/28/17 / #20170275270

Benzyl substituted indazoles

Compounds of formula (i) and their use as pharmaceuticals.. . ... Bayer Pharma Aktiengesellschaft

09/28/17 / #20170275269

Benzyl substituted indazoles as bub1 kinase inhibitors

Compounds of formula (i) and their use as pharmaceuticals.. . ... Bayer Pharma Aktiengesellschaft

09/28/17 / #20170275268

Heteroaryl substituted indazoles

Compounds of formula (i), which are inhibitors of bub 1 kinase, processes for their production and their use as pharmaceuticals.. . ... Bayer Pharma Aktiengesellschaft

09/28/17 / #20170275267

Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer

Compounds of formula (i), processes for their production and their use as bub1 kinase inhibitors for the treatment of hyperproliferative diseases and/or disorders responsive to induction of cell death.. . ... Bayer Pharma Aktiengesellschaft

09/28/17 / #20170273980

Benzyl substituted indazoles as bub1 inhibitors

Compounds of formula (i) as defined herein and their use as pharmaceuticals.. . ... Bayer Pharma Aktiengesellschaft

09/21/17 / #20170267648

Substituted uracils as chymase inhibitors

The present application relates to novel substituted uracil derivatives, to a method for the production thereof, to the use thereof either alone or in combination for treating and/or preventing diseases, and to the use thereof for producing pharmaceuticals for the treatment and/or prevention of diseases.. . ... Bayer Pharma Aktiengesellschaft

09/14/17 / #20170260226

3-nitrogen or sulphur substituted oestra-1,3,5(10),16-tetraene akr1c3 inhibitors

The invention relates to akr1c3 inhibitors of formula (i) and to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of bleeding disorders and endometriosis.. . ... Bayer Pharma Aktiengesellschaft

09/14/17 / #20170260198

Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases

Compounds of formula (1) which are inhibitors of bub 1 kinase, processes for their production and their use as pharmaceuticals.. . ... Bayer Pharma Aktiengesellschaft

09/14/17 / #20170260139

Novel 5-aminotetrahydroquinoline-2-carboxylic acids and their use

The present application relates to novel 5-amino-5,6,7,8-tetrahydroquinoline-2-carboxylic acids, to processes for their preparation, to their use for the treatment and/or prevention of diseases, and to their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular and cardiopulmonary disorders.. . ... Bayer Pharma Aktiengesellschaft

09/07/17 / #20170253602

Substituted pyridobenzodiazepinone-derivatives and use thereof

The present application relates to novel (3-hydroxyphenyl)amino-substituted pyrido[2,3-b][1,5]benzodiazepin-5-one derivatives, to processes for preparation thereof, to the use thereof alone or in combination for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially of angiogenic disorders and hyperproliferative disorders in which neovascularization plays a role, for example ophthalmological disorders and cancers and tumours. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.. ... Bayer Pharma Aktiengesellschaft

08/24/17 / #20170240566

Amino-substituted annulated pyrimidines and use thereof

The present application relates to novel amino-substituted fused pyrimidines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.. . ... Bayer Pharma Aktiengesellschaft

08/24/17 / #20170239251

(aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use

The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.. . ... Bayer Pharma Aktiengesellschaft

08/17/17 / #20170233413

Substituted annulated pyrimidines and use thereof

The present application relates to novel substituted fused pyrimidines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.. . ... Bayer Pharma Aktiengesellschaft

08/17/17 / #20170233345

Substituted quinoline-4-carboxamides and use thereof

The present application relates to novel substituted quinoline-4-carboxamides and use thereof, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.. . ... Bayer Pharma Aktiengesellschaft

08/10/17 / #20170226092

Fluorinated benzofuranyl-pyrimidine derivatives containing a suflone group

The present invention relates to fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group of general formula (i) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyperproliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (i). ... Bayer Pharma Aktiengesellschaft

08/10/17 / #20170226081

Glucose transport inhibitors

The present invention relates to chemical compounds that selectively inhibit glucose transporter 1 (glut1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.. . ... Bayer Pharma Aktiengesellschaft

08/10/17 / #20170225442

Laminate changing device

A device for translaminating tension-sensitive films from a first liner to a second liner, wherein the device has a first transport device, a second transport device, and a laminating device. The first transport device is configured to transport a first laminated strip to a film delaminating station. ... Bayer Pharma Aktiengesellschaft

08/03/17 / #the present invention relates to a novel and improved process for preparing (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (i)

Bayer Pharma Aktiengesellschaft

. . ... Bayer Pharma Aktiengesellschaft

08/03/17 / #20170217954

Cyano-substituted imidazo[1,2-a]pyridinecarboxamides and their use

The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.. . ... Bayer Pharma Aktiengesellschaft

08/03/17 / #20170217946

Amino-substituted isoxazoles

The present invention relates to amino-substituted isoxazoles of general formula (i): in which a, r1 and r2 are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

08/03/17 / #20170217938

Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group

The present invention relates to fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group of general formula (i) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (i).. ... Bayer Pharma Aktiengesellschaft

08/03/17 / #20170216304

2-(morpholin-4-yl)-1,7-naphthyridines

The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (i) or (ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

07/27/17 / #20170210738

Glucose transport inhibitors

The present invention relates to chemical compounds of formula (i) that selectively inhibit glucose transporter 1 (glut1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.. . ... Bayer Pharma Aktiengesellschaft

07/20/17 / #20170202815

5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group

The present invention relates to 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group of general formula (i) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (i).. ... Bayer Pharma Aktiengesellschaft

07/13/17 / #20170197979

Benzothiadiazolamines

The present invention relates to substituted benzothiadiazolamine compounds of general formula (i) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

07/13/17 / #20170197922

Benzimidazol-2-amines as midh1 inhibitors

The present invention relates to benzimidazol-2-amines of general formula (i): in which r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11 and r12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

07/13/17 / #20170197921

Benzimidazol-2-amines as midh1 inhibitors

The present invention relates to benzimidazol-2-amines of general formula (i), in which r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11 and r12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

06/29/17 / #20170182014

Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use

The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.. . ... Bayer Pharma Aktiengesellschaft

05/04/17 / #the present invention relates to bet protein-inhibitory, especially brd4-inhibitory 3,4-dihydropyrido[2,3-b]pyrazinones with a meta-substituted aromatic amino or ether group of the general formula (i)

Bayer Pharma Aktiengesellschaft

. . ... Bayer Pharma Aktiengesellschaft

05/04/17 / #20170121315

Heterobicyclically substituted 4-oxobutane acid derivatives and use thereof

The present application relates to novel heterobicyclically substituted 4-oxobutanoic acid derivatives, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases and to their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of respiratory, pulmonary and cardiovascular disorders.. . ... Bayer Pharma Aktiengesellschaft

05/04/17 / #20170119776

Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof

The present application relates to novel, chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives, to a method for their preparation, to their use on their own or in combinations for the treatment and/or prevention of diseases, and to their use for producing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diseases of the respiratory tracts, the lung and the cardiovascular system.. . ... Bayer Pharma Aktiengesellschaft

04/27/17 / #20170114070

Inhibitors of the wnt signalling pathways

The present invention relates to inhibitors of the wnt signalling pathways of general formula (i) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

04/27/17 / #20170114049

2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratory tract diseases

The present application relates to novel 2,5-disubstituted cyclopentanecarboxylic acid derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of respiratory, pulmonary and cardiovascular disorders.. . ... Bayer Pharma Aktiengesellschaft

04/20/17 / #20170107229

Substituted tetrahydropyridothienopyrimidines

The present invention relates to substituted tetrahydropyridothienopyrimidine compounds of general formula (i) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

04/20/17 / #20170107212

Novel compounds

The present invention relates to inhibitors of the wnt signalling pathways of general formula (i) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

04/13/17 / #20170101407

6-chlorine-substituted imidazo[1,2-a]pyridine carboxamides and the use thereof as soluble guanylate cyclase stimulators

The present application relates to novel 6-chloro-substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.. . ... Bayer Pharma Aktiengesellschaft

04/13/17 / #20170101391

3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones

Compounds of formula (i) which are inhibitors of bub1 kinase, processes for their production and their use as pharmaceuticals.. . ... Bayer Pharma Aktiengesellschaft

03/02/17 / #20170057958

Enantiomers of the n-(2-amino-5-fluoro-2-methylpentyl)-8-[(2,6-difluorobenzyl)oxy]-2-methylimidazo[1,2-a]pyridine-3-carboxamide, as well as of the di- and trifluoro derivatives for the treatment of cardiovascular diseases

The present application relates to novel 6-hydrogen-substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.. . ... Bayer Pharma Aktiengesellschaft

03/02/17 / #20170057954

Substituted imidazo[1,2-a]pyridinecarboxamides and their use

The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.. . ... Bayer Pharma Aktiengesellschaft

02/23/17 / #20170050962

Imidazo[1,2-a]pyridines as stimulators of soluble guanylate cyclase for treating cardiovascular diseases

The present application relates to novel heterocyclyl- and heteroaryl-substituted imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.. . ... Bayer Pharma Aktiengesellschaft

02/23/17 / #20170050961

Imidazo[1,2-a]pyridines as soluble guanylate cyclase stimulators for the treatment of cardiovascular diseases

The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.. . ... Bayer Pharma Aktiengesellschaft

02/09/17 / #20170037028

Glucose transport inhibitors

The present invention relates to chemical compounds that selectively inhibit glucose transporter 1 (glut1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.. . ... Bayer Pharma Aktiengesellschaft

02/09/17 / #20170035739

Substituted oxopyridine derivatives and use thereof as factor xia/plasma

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.. . ... Bayer Pharma Aktiengesellschaft

02/02/17 / #20170029441

Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders

The present invention relates to amido-substituted imidazopyridazine compounds of general formula (i): in which a, e, r2, r3, r4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

02/02/17 / #20170029439

Novel macrocyclic compounds

The present invention relates to novel macrocyclic compounds of general formula (i) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (i).. ... Bayer Pharma Aktiengesellschaft

01/26/17 / #20170022171

2,5-disubstituted cyclopentanecarboxylic acids and their use

The present application relates to novel 2,5-disubstituted cyclopentanecarboxylic acid derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of respiratory, pulmonary and cardiovascular disorders.. . ... Bayer Pharma Aktiengesellschaft

01/26/17 / #20170020886

Amido-substituted azole compounds

The present invention relates to amido-substituted azole compounds of general formula (i), in which x1, x2, r1, r2, r4, r5, r7 and r8 are as defined in the claims which are inhibitors of tnks1 and/or tnks2, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.. . ... Bayer Pharma Aktiengesellschaft

01/26/17 / #20170020876

Bicyclically substituted uracils and the use thereof

The present application relates to novel bicyclically substituted uracil derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases.. . ... Bayer Pharma Aktiengesellschaft

01/26/17 / #20170020875

Bicyclically substituted uracils and the use thereof

The present application relates to novel bicyclically substituted uracil derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases.. . ... Bayer Pharma Aktiengesellschaft

01/19/17 / #20170015634

Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group

The present invention relates to 5-fluoro pyrimidine derivatives containing a sulfondiimine group of general formula (i) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (i).. ... Bayer Pharma Aktiengesellschaft

01/12/17 / #20170008876

Metal chelate compounds for binding to the platelet specific glycoprotein iib/iiia

The present invention is directed to compounds that bind to glycoprotein iib/iiia and can be used for diagnostic imaging, in particular magnetic resonance imaging of thrombi. The disclosed compounds enable the binding to glycoprotein iib/iiia receptor combined with an adequate imaging sensitivity.. ... Bayer Pharma Aktiengesellschaft

01/05/17 / #20170001989

5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group

The present invention relates to 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group of general formula (i) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (i).. ... Bayer Pharma Aktiengesellschaft








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Bayer Pharma Aktiengesellschaft in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Bayer Pharma Aktiengesellschaft with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###